Short answer · Medically reviewed summary · Last updated: 2026-05-08
Fetal Valproate Syndrome (FVS) is an estimated condition affecting approximately 1% to 10% of children exposed to valproate in utero, though precise global prevalence remains difficult to determine due to significant underreporting. As a preventable teratogenic condition, the incidence of Fetal Valproate Syndrome fluctuates based on regional prescription practices for valproate-based medications used to treat epilepsy and bipolar disorder. What is the estimated prevalence of Fetal Valproate Syndrome? Because Fetal Valproate Syndrome is caused by environmental exposure rather than a genetic mutation, prevalence is tied directly to the clinical use of valproate.
What is the prevalence of Fetal Valproate Syndrome?
Prevalence of Fetal Valproate Syndrome: how many people are affected worldwide, differences by sex and region, with sources.
Fetal Valproate Syndrome (FVS) is an estimated condition affecting approximately 1% to 10% of children exposed to valproate in utero, though precise global prevalence remains difficult to determine due to significant underreporting. As a preventable teratogenic condition, the incidence of Fetal Valproate Syndrome fluctuates based on regional prescription practices for valproate-based medications used to treat epilepsy and bipolar disorder.
What is the estimated prevalence of Fetal Valproate Syndrome?
Because Fetal Valproate Syndrome is caused by environmental exposure rather than a genetic mutation, prevalence is tied directly to the clinical use of valproate. Studies suggest that of pregnancies exposed to valproate, roughly 10% may result in major congenital malformations, and a significant percentage of those children will exhibit the cognitive and behavioral traits characteristic of Fetal Valproate Syndrome. It is considered a rare condition in terms of public health recognition, but it is likely underdiagnosed in clinical settings.
How does Fetal Valproate Syndrome affect different populations?
The impact of Fetal Valproate Syndrome does not show a clear predilection for specific ethnicities, though geographic prevalence varies based on local healthcare regulations regarding the use of valproate in women of childbearing age. The syndrome affects both males and females, though some literature suggests subtle differences in the expression of neurodevelopmental outcomes. Key factors influencing the severity of Fetal Valproate Syndrome include:
- Dosage: Higher maternal doses of valproate are strongly correlated with increased risk.
- Timing: Exposure during the first trimester is most critical for physical malformations.
- Polytherapy: Use of valproate in combination with other anti-seizure medications may increase risk.
Why is accurate data for Fetal Valproate Syndrome limited?
Accurate tracking of Fetal Valproate Syndrome is hindered by diagnostic challenges. Many children are misdiagnosed with idiopathic autism or ADHD, as the clinical presentation often overlaps with these conditions. Currently, two individuals in the DiseaseMaps.org community have shared their lived experiences with Fetal Valproate Syndrome, providing a vital, albeit small, real-world perspective on the lifelong nature of this syndrome from childhood into adulthood.
Next steps
- Consult a clinical geneticist or pediatric neurologist to discuss diagnostic criteria for Fetal Valproate Syndrome.
- Connect with the DiseaseMaps.org community to share experiences and find support with others affected by Fetal Valproate Syndrome.
- Review updated safety guidelines from your national health authority regarding the use of valproate during pregnancy.
Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.
References
- Orphanet: Valproate-induced embryopathy (ORPHA:99912)
- NIH Genetic and Rare Diseases Information Center (GARD): Fetal Valproate Syndrome
- European Medicines Agency (EMA): Valproate Pregnancy Prevention Programme
